Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Investigate Safe and Tolerable Dose of GMA301 Injection in Healthy Volunteers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04505137
Recruitment Status : Completed
First Posted : August 10, 2020
Last Update Posted : September 1, 2021
Sponsor:
Collaborators:
Metaclinical
Syneos Heath
Information provided by (Responsible Party):
Gmax Biopharm LLC. ( Gmax Biopharm Australia Pty Ltd. )

Brief Summary:
This study is a single-centre, randomized, double-blind, placebo-controlled, dose escalation study to assess the safety, tolerability and PK of GMA301 Injection in healthy subjects. Two sequential dosing cohorts (at ascending dose fashion), each with 6 subjects receiving GMA301 Injection and 2 subjects receiving placebo (total of 16 subjects), will be given single doses. The doses to be administered in the two cohorts will be 1500 mg and 2000 mg respectively, or matching placebo

Condition or disease Intervention/treatment Phase
Pulmonary Arterial Hypertension Drug: GMA301 Injection Other: GMA301 Placebo Injection Phase 1

Detailed Description:
The current study is an extension of the previous study #1010218 (ACTRN12618000121268) to further explore the safety and PK profile of GMA301 injection at higher dosage. The SRC (Safety Review Committee) will be responsible for the assessment of safety, tolerability, and PK data for each dose level and to make decisions with regards to study progression. A Statistical Analysis Plan (SAP) will be written after finalizing the protocol and prior to database lock. The SAP will detail the implementation of all the planned statistical analyses in accordance with the principal features stated in the protocol. Adverse events will be coded using the Medical Dictionary for Regulatory Activities (MedDRA).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 16 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Intervention Model Description: Two sequential dosing cohorts, each with 6 subjects receiving GMA301 Injection and 2 subjects receiving placebo (total of 16 subjects). The doses to be administered will be 1500 mg and 2000 mg, or matching placebo, single dosing. Each cohort will include at least 2 participants of Chinese descent, if possible.
Masking: Double (Participant, Investigator)
Masking Description: The subjects and the clinical personnel involved in the collection, monitoring, revision, or evaluation of AEs, or personnel who could have an impact on the outcome of the study will be blinded with respect to the subject's treatment assignment (GMA301 Injection or placebo). Blinding will be maintained at least until the clinical phase of the study is completed (i.e., when reporting and evaluation of all AEs have been completed, for all cohorts).
Primary Purpose: Treatment
Official Title: A Phase 1, Placebo-Controlled, Double-Blind, Dose-Escalation Study To Investigate The Safety, Tolerability, And Pharmacokinetics Of A Single Intravenous Dose Of GMA301 Injection In Healthy Volunteers
Actual Study Start Date : September 2, 2020
Actual Primary Completion Date : March 19, 2021
Actual Study Completion Date : March 19, 2021


Arm Intervention/treatment
Experimental: GMA301 1500mg Or Placebo Injection
Two sentinel subjects (1 active and 1 placebo) will be dosed first and then reaming 6 subjects will dosed within 7 days. The dose to be administered is 1500 mg single Intravenous dose of GMA301 Injection.
Drug: GMA301 Injection
GMA301 Injection administered as a single dose of 1500 mg

Other: GMA301 Placebo Injection
GMA301 Injection without GMA301 administered as a single intravenous dose

Experimental: GMA301 2000mg Or Placebo Injection
Two sentinel subjects (1 active and 1 placebo) will be dosed first and then reaming 6 subjects will dosed within 7 days. The dose to be administered is 2000 mg single intravenous dose of GMA301 Injection.
Other: GMA301 Placebo Injection
GMA301 Injection without GMA301 administered as a single intravenous dose

Drug: GMA301 Injection
GMA301 Injection administered as a single dose of 2000 mg




Primary Outcome Measures :
  1. Safety and Tolerability [ Time Frame: All AEs (adverse events) will be captured from the time the investigator received the signed ICF (informed consent form) of subjects until study completion ie Day 70 ]
    To assess the safety and tolerability of GMA301 Injection following single escalating intravenous (IV) injections in healthy subjects.


Secondary Outcome Measures :
  1. Pharmacokinetics Profile [ Time Frame: Blood PK samples will be collected for analysis during the treatment period at: pre-dose and 4 hours, 8 hours, 24 hours, 72 hours, 168 hours post-dose (Day 7), Day 14, Day 21, Day 28, Day 42, Day 56 and Day 70 ]
    PK parameters determined is AUC(0-inf)

  2. Pharmacokinetics Profile [ Time Frame: Blood PK samples will be collected for analysis during the treatment period at: pre-dose and 4 hours, 8 hours, 24 hours, 72 hours, 168 hours post-dose (Day 7), Day 14, Day 21, Day 28, Day 42, Day 56 and Day 70 ]
    PK parameters determined is AUC(0-t)

  3. Pharmacokinetics Profile [ Time Frame: Blood PK samples will be collected for analysis during the treatment period at: pre-dose and 4 hours, 8 hours, 24 hours, 72 hours, 168 hours post-dose (Day 7), Day 14, Day 21, Day 28, Day 42, Day 56 and Day 70 ]
    PK parameters determined is C(max)

  4. Pharmacokinetics Profile [ Time Frame: Blood PK samples will be collected for analysis during the treatment period at: pre-dose and 4 hours, 8 hours, 24 hours, 72 hours, 168 hours post-dose (Day 7), Day 14, Day 21, Day 28, Day 42, Day 56 and Day 70 ]
    PK parameters determined is residual area

  5. Pharmacokinetics Profile [ Time Frame: Blood PK samples will be collected for analysis during the treatment period at: pre-dose and 4 hours, 8 hours, 24 hours, 72 hours, 168 hours post-dose (Day 7), Day 14, Day 21, Day 28, Day 42, Day 56 and Day 70 ]
    PK parameters determined is T(max)

  6. Pharmacokinetics Profile [ Time Frame: Blood PK samples will be collected for analysis during the treatment period at: pre-dose and 4 hours, 8 hours, 24 hours, 72 hours, 168 hours post-dose (Day 7), Day 14, Day 21, Day 28, Day 42, Day 56 and Day 70 ]
    PK parameters determined is T(1/2 el)

  7. Pharmacokinetics Profile [ Time Frame: Blood PK samples will be collected for analysis during the treatment period at: pre-dose and 4 hours, 8 hours, 24 hours, 72 hours, 168 hours post-dose (Day 7), Day 14, Day 21, Day 28, Day 42, Day 56 and Day 70 ]
    PK parameters determined is K(el)

  8. Dose for GMA301 Injection for subsequent clinical studies [ Time Frame: All AEs will be captured from the time the investigator received the signed ICF of subjects until study completion ie Day 70 ]
    To identify appropriate doses of GMA301 Injection for subsequent clinical studies



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Non-smoker (no use of tobacco or nicotine products within 2 months prior to screening) with BMI > 18.5 and < 30.0 kg/m2 and body weight ≥ 50.0 kg for males and ≥ 45.0 kg for females. Each cohort will include at least 2 participants of Chinese descent, if possible.
  2. Healthy as defined by:

    1. The absence of clinically significant illness and surgery within 4 weeks prior to dosing.
    2. The absence of clinically significant history of neurological, endocrine, cardiovascular, respiratory, hematological, immunological, psychiatric, gastrointestinal, renal, hepatic, and metabolic disease.
  3. Females of childbearing potential who are sexually active with a male partner must be willing to use one of the following acceptable contraceptive methods throughout the study and for 6 months after the last study drug administration:

    1. Oral, injected, or implanted hormonal methods of contraception in combination with a barrier method;
    2. Placement of an intrauterine device (IUD) or intrauterine system (IUS) in combination with a barrier method;
    3. Sterilized male partner (with the appropriate post-vasectomy documentation of the absence of sperm in the ejaculate) in combination with a barrier method;
    4. True abstinence, when this is in line with the subject's preferred and usual lifestyle.
  4. Male subjects must agree to avoid causing pregnancy by using a reliable method of birth control during the study and for 6 months after study drug administration and must be willing to use one of the following acceptable contraceptives:

    1. Simultaneous use of a male condom and, for the female partner, hormonal contraceptives used since at least 4 weeks or intra-uterine contraceptive device placed since at least 4 weeks;
    2. Simultaneous use of a male condom and, for the female partner, a diaphragm or cervical cap.
  5. Male subjects (including men who have had a vasectomy) with a pregnant partner must agree to use a condom from the first study drug administration until at least 6 months after study drug administration.
  6. Male subjects must be willing not to donate sperm during the study and for 6 months following study drug administration.
  7. Capable of consent.

Exclusion Criteria:

  1. Any clinically significant abnormality at physical examination, clinically significant abnormal laboratory test results or positive test for HIV, hepatitis B, or hepatitis C found during medical screening.
  2. Presence or history of any clinically significant chronic condition of the neurological, respiratory, cardiovascular, gastrointestinal, urogenital, reproductive, musculoskeletal, endocrine system or cancer.
  3. Clinically significant (as judged by the investigator) presence of acute illness (e.g., gastrointestinal illness, infection such as influenza, upper respiratory tract infection) upo admission to the study site.
  4. Alanine aminotransferase and/or aspartate aminotransferase above the upper limit of normal.
  5. Positive urine drug screen or alcohol breath test at screening.
  6. Positive pregnancy test at screening.
  7. Clinically significant ECG abnormalities or vital sign abnormalities (systolic blood pressure lower than 90 or over 140 mmHg, diastolic blood pressure lower than 60 or over 90 mmHg,or heart rate less than 40 or over 100 bpm) at screening. Up to 2 additional measurements may be taken after an appropriate resting interval (at least 10 minutes) at Screening to confirm eligibility.
  8. History of type 1 hypersensitivity or severe cutaneous adverse reaction to any medication, or to any excipient in the formulation, or history of significant atopy.
  9. Hemoglobin below lower limit of normal.
  10. Women who intend to become pregnant or are lactating.
  11. History of significant alcohol abuse within 1 year prior to screening or regular use of alcohol within 6 months prior to the screening visit (average weekly alcohol intake that exceeds 14 units per week (males) or 7 units (females) per week, or are unwilling to stop alcohol consumption for 24 hours prior to study drug dosing until the completion of the study (1 unit = 12 oz or 360 mL of beer; 5 oz or 150 mL of wine;1.5 oz or 45 mL of distilled spirits).
  12. History of significant drug abuse within 1 year prior to screening or use of soft drugs (such as marijuana) within 3 months prior to the screening visit or hard drugs (such as cocaine, phencyclidine (PCP), crack, opioid derivatives including heroin, and amphetamine derivatives) within 1 year prior to screening.
  13. Participation in a clinical research study involving the administration of an investigational or marketed drug or device within 30 days prior to dosing, administration of a biological product in the context of a clinical research study within 90 days prior to dosing, or concomitant participation in an investigational study involving no drug or device administration.
  14. Use of prescription medications or over-the-counter medications within 7 days prior to study drug administration, with the exception of simple analgesics such as paracetamol and routine vitamins.
  15. Donated more than 500 mL of blood within 4 weeks prior to study enrollment, or donated plasma or participated in a plasmapheresis program within 7 days of study drug administration.
  16. Any reason which, in the opinion of the Investigator, would prevent the subject from participating in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04505137


Locations
Layout table for location information
Australia, South Australia
CMAX Clinical Research
Adelaide, South Australia, Australia, 5000
Sponsors and Collaborators
Gmax Biopharm Australia Pty Ltd.
Metaclinical
Syneos Heath
Investigators
Layout table for investigator information
Principal Investigator: Sepehr Shakib, Dr CMAX Clinical Research
Layout table for additonal information
Responsible Party: Gmax Biopharm Australia Pty Ltd.
ClinicalTrials.gov Identifier: NCT04505137    
Other Study ID Numbers: GETA_SAD_02
First Posted: August 10, 2020    Key Record Dates
Last Update Posted: September 1, 2021
Last Verified: November 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypertension
Vascular Diseases
Cardiovascular Diseases